SNGX - Soligenix Inc
Soligenix Inc Logo

SNGX - Soligenix Inc

https://www.soligenix.com
Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

Soligenix, Inc., an advanced stage biopharmaceutical company, focuses on developing and marketing products to treat rare diseases in the United States. The company is headquartered in Princeton, New Jersey.

52W High
$6.23
52W Low
$1.09
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
2.06
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-0.12
EV/Revenue (<3 favorable)
1.87
P/S (TTM) (<3 favorable)
3874.85
P/B (<3 favorable)
6.70
Ownership
Retail‑heavy
Source: Overview
Insiders (1–5% typical)
0.02%
Institutions (25–75% balanced)
4.43%
Shares Outstanding
4,285,600
Float
4,284,900
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
0
Gross Profit (TTM)
0
EPS (TTM)
-3.06
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-3.91%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
-1.00
Momentum
Bearish momentum
Value
0.0401
Previous
0.0395
Trend
Rising
Signal Cross
No cross
As of
Sep. 12, 2025